Lv5
940 积分 2020-12-07 加入
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma
9小时前
待确认
Efficacy of locoregional treatment for oligo-drug-resistant lesions during first-line atezolizumab plus bevacizumab therapy for unresectable hepatocellular carcinoma: a single-center retrospective study
9小时前
求助中
Emerging evidence for adapting radiotherapy to immunotherapy
5天前
已完结
Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization
6天前
已完结
Durvalumab and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
7天前
已完结
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice
7天前
已关闭
A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma
7天前
已完结
Dual Immunotherapy Makes Strides against HCC
7天前
已关闭
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide
8天前
已完结
Spatial immune scoring system predicts hepatocellular carcinoma recurrence
10天前
已完结
皖公网安备34019202002308
